How Peptide Regulations Differ Between Indonesia and Other Countries

The same peptide can occupy very different positions depending on which country you are standing in.

A product may be openly advertised online in Bali.

The same type of product may attract an FDA warning letter in the United States.

Australian regulators may intercept it at the border or take action against its commercial supply.

In the United Kingdom, an unlicensed medicine may sometimes be supplied through a tightly controlled "specials" pathway for an individual patient's clinical need — while public advertising of that same unlicensed medicine is prohibited.

That does not mean one country has decided the peptide works while another has decided it does not.

It means pharmaceutical regulation is more complicated than the words legal and illegal suggest.

For peptides, regulators may separately control:

• marketing authorisation
• prescribing
• manufacturing
• compounding
• clinical research
• importation
• online distribution
• advertising
• supply to patients

That distinction is particularly important in Indonesia, where approved medicines such as semaglutide and tirzepatide now appear in some of the same online conversations as experimental compounds such as BPC-157, TB-500 and retatrutide.

As of 3 October 2026, those substances should not be treated as one regulatory category.

There is no single international law called "peptide regulation".

Each jurisdiction regulates specific products and activities through its own medicines framework.

In Indonesia, BPOM grants marketing authorisations to specific finished medicinal products. Wegovy containing semaglutide has identifiable BPOM registration records, while Mounjaro KwikPen containing tirzepatide received Indonesian marketing authorisation for type 2 diabetes in February 2026 and an additional weight-management indication in July 2026.

Experimental products are a separate question. Indonesia has a formal BPOM clinical-trial pathway requiring Persetujuan Pelaksanaan Uji Klinik, or PPUK, for regulated pre-marketing and post-marketing clinical trials.

The United States, Australia and United Kingdom also distinguish approved medicines from investigational or unapproved products, but the mechanisms for compounding, special access, importation and advertising differ significantly.

So the useful question is not:

"Are peptides legal in this country?"

It is:

"Which peptide, which product, for what purpose, and what activity are we talking about?"

The word peptide describes a type of molecule.

It does not automatically tell you how regulators classify a finished product.

Consider four examples.

Semaglutide

Semaglutide is a peptide-based active ingredient contained in approved medicines.

Indonesia has BPOM-registered Wegovy products containing semaglutide.

Tirzepatide

Tirzepatide is also contained in an approved Indonesian medicine.

BPOM's database identifies Mounjaro KwikPen and records an original Indonesian approval on 11 February 2026, followed by an additional weight-management indication on 2 July 2026.

Retatrutide

Retatrutide remains investigational.

The FDA currently states that retatrutide is not a component of an FDA-approved drug, has not been found safe and effective for any condition and cannot be used in drug compounding under US federal law.

BPC-157 and TB-500

Neither BPC-157 nor TB-500 is simply another version of an approved GLP-1 medicine.

FDA has identified substantial information gaps around both compounds, including limited or absent human safety information and concerns relevant to compounded products.

Putting all four substances under the heading "peptides" therefore tells us almost nothing about their regulatory position.

Several terms are frequently mixed together online.

They should not be.

This is why describing BPC-157 simply as "illegal" is usually too imprecise.

Are we discussing commercial sale?

Human prescribing?

Personal possession?

Importation?

Clinical research?

Manufacturing?

Advertising?

Those questions can produce different answers.

For readers in Bali, Indonesia's own regulatory framework matters more than what the FDA says about a product in America.

The FDA can provide useful scientific information.

It cannot grant Indonesian marketing authorisation.

That authority belongs to BPOM.

BPOM registration applies to specific medicinal products.

The clearest recent example is tirzepatide.

BPOM announced that tirzepatide received Indonesian marketing authorisation in February 2026 for type 2 diabetes and an additional weight-management indication in July 2026.

BPOM's own registration database identifies Mounjaro KwikPen, the active ingredient tirzepatide, the product strength, route of administration and Indonesian marketing-authorisation number.

This illustrates an important regulatory principle:

An active ingredient being approved somewhere in Indonesia does not mean every vial carrying that ingredient's name is an approved product.

Authorisation belongs to the registered finished medicinal product and its approved particulars.

The same principle applies to semaglutide. BPOM maintains specific registration entries for Wegovy products rather than granting a generic approval to every product that claims to contain semaglutide.

This distinction is explored further in Peptides Pro's Tirzepatide vs BPC-157 in Bali: Why One Is a Medicine and the Other Isn't.

Absence of marketing authorisation does not mean a substance can never be studied in Indonesia.

BPOM regulates clinical trials separately.

Its current clinical-trial information states that pre-marketing trials include studies of products that do not yet have Indonesian marketing authorisation.

Those trials require Persetujuan Pelaksanaan Uji Klinik, or PPUK, from BPOM and must operate within Good Clinical Practice requirements and ethics oversight.

This is a crucial difference between:

an investigational product used inside an authorised clinical trial

and

a product commercially sold to consumers as though it were an ordinary approved medicine.

The substance may have the same name.

The regulatory circumstances are completely different.

Online availability is not evidence that a product is legally authorised.

BPOM Regulation No. 14 of 2024 governs the online distribution of medicines and other regulated products and remains in force as amended by BPOM Regulation No. 30 of 2025.

Indonesia's healthcare licensing rules also limit telepharmacy supply of injectable preparations, with an exception for insulin under specified circumstances.

This becomes relevant to Bali's peptide market because many products promoted online are injectable.

Whether a particular research-labelled product legally falls within the definition of a medicinal product requires product-specific analysis.

It would therefore be incorrect to say:

"All injectable research peptides are automatically illegal to sell online in Indonesia."

But it would be equally incorrect to assume:

"A peptide must be legal because a Bali website delivers it."

Commercial availability and regulatory authorisation are different facts.

BPOM Regulation No. 7 of 2026 introduced updated rules governing drug promotion and advertising.

BPOM specifically highlighted a new prohibition on using two-way communication features on social media as a means of conducting medicine purchase transactions.

The agency also strengthened rules involving influencers, medicine samples, commissions and excessive discounts.

That is particularly relevant as Bali medicine and peptide commerce increasingly moves through Instagram and messaging platforms.

Again, classification matters.

The rule concerns medicines.

Whether a particular product marketed as a "research peptide" is legally classified as a medicine cannot be determined solely from the words printed on the seller's website.

The US regulatory model is often quoted in peptide discussions, but several different FDA frameworks are routinely mixed together.

A company cannot simply sell a new drug for human treatment in interstate commerce because the active molecule has interesting research behind it.

FDA warning letters issued in 2026 demonstrate the agency treating internet products marketed as retatrutide and other peptide-related drugs as unapproved new drugs when they were marketed for human therapeutic use without approved applications.

A website labelling something a "peptide" does not place it outside drug regulation when the surrounding claims establish intended therapeutic use.

This distinction matters enormously.

Compounded drugs are not FDA-approved drugs.

FDA does not review each compounded drug for safety, effectiveness and quality before it reaches the market.

Retatrutide provides a particularly clear example.

FDA currently states that retatrutide cannot be used in drug compounding under federal law and has not been found safe and effective for any condition.

BPC-157 and TB-500 occupy another part of the compounding debate.

In July 2026, the FDA Pharmacy Compounding Advisory Committee considered BPC-157-related and TB-500-related bulk substances for possible inclusion on the Section 503A bulks list.

FDA has separately identified potential significant safety concerns for BPC-157 and TB-500-related substances, including immunogenicity, peptide-related impurities and major gaps in human safety information.

A discussion about whether a substance may qualify for a particular compounding pathway should not be described as FDA approval of the substance as a medicine.

They are different regulatory processes.

The US also demonstrates why unapproved does not automatically mean completely unavailable under every circumstance.

FDA operates an Expanded Access pathway for certain patients with serious or immediately life-threatening conditions who cannot participate in clinical trials and have no satisfactory alternative therapy.

The physician, FDA, institutional review board and manufacturer may all have roles in permitting access.

That is controlled access to an investigational product.

It is not equivalent to purchasing an internet vial promoted as a "research peptide".

Australia is useful for comparison because the Therapeutic Goods Administration has published extensive peptide-specific guidance in 2026.

The TGA explicitly names:

• BPC-157
• GHK-Cu
• TB-500
• retatrutide
• CJC-1295

as examples of unapproved peptide products that may appear in Australia's market.

Australian therapeutic goods intended for ordinary supply generally operate through the Australian Register of Therapeutic Goods.

Unapproved peptide products have not gone through the standard TGA assessment for quality, safety and effectiveness.

The regulator has repeatedly warned consumers and businesses about online promotion and supply of such products.

In August 2026, the TGA announced a seizure involving products including retatrutide, CJC-1295 and a BPC-157/TB-500 "Wolverine Stack" and described the alleged commercial importation, advertising and supply as unlawful activity.

That does not mean every possible form of access to an unapproved medicine is prohibited.

Australia permits access to certain unapproved therapeutic goods through defined pathways including:

• Special Access Scheme
• Authorised Prescriber Scheme
• Clinical Trial schemes
• Personal Importation Scheme

Each has its own requirements.

Under the Special Access Scheme, for example, registered health practitioners may apply to access an unapproved therapeutic good for an individual patient under specified conditions.

Australia's Personal Importation Scheme can also permit individuals to import some unapproved therapeutic goods for personal use when the scheme's requirements and any other applicable controls are met.

This illustrates the central point of this article.

“Unapproved in Australia” and “no lawful pathway can ever exist” are not equivalent statements.

But neither does the existence of special-access pathways authorise unrestricted retail sale.

The TGA has made unapproved peptide products a compliance priority.

It has warned that businesses and individuals can face enforcement over unlawful advertising, importation, manufacture or supply.

Australia has also pursued legal action concerning advertising of peptides such as BPC-157 and CJC-1295.

This is a much more explicit public enforcement posture than readers may encounter when searching Indonesian sources, where there is not currently an equivalent BPOM webpage grouping the major gray-market peptides together into one public peptide-specific regulatory warning.

That does not mean Indonesia permits them.

It means the regulators communicate and organise their rules differently.

The UK provides another useful distinction.

Under MHRA rules, a medicine without UK marketing authorisation may in some circumstances be supplied as an unlicensed medicinal product, often called a "special".

But this is not an open route for selling any experimental peptide consumers request.

MHRA guidance states that "specials" can be supplied for an individual patient's treatment where an appropriately authorised prescriber identifies a special clinical need that cannot be met by an available licensed medicine.

Manufacturing and importation also require appropriate licences.

For imported unlicensed medicines, the importer must hold the relevant licence and generally notify the MHRA before importation; MHRA can object.

Again:

unlicensed access through a regulated clinical pathway

is not the same thing as

general commercial availability of an experimental peptide.

MHRA guidance states that:

• prescription-only medicines cannot be advertised to the general public
• medicines without the appropriate marketing authorisation cannot be advertised as medicines

In 2026, MHRA specifically warned businesses against promoting pipeline weight-management products before UK marketing authorisation.

This is directly relevant to compounds such as retatrutide.

A business creating consumer demand for a medicine before regulatory authorisation can encounter advertising restrictions even before the question of actual supply arises.

The major differences become clearer when the same regulatory questions are compared side by side.

This table is a framework, not a legal opinion on a particular transaction.

Individual substances can also be affected by additional controlled-substance, customs, pharmacy, professional, sporting or state-level rules.

Suppose someone sees BPC-157 advertised online.

What can they accurately conclude?

Very little from the advertisement itself.

In the United States

FDA has not approved a BPC-157 medicine and has highlighted major safety-information gaps relevant to compounding.

In Australia

TGA explicitly lists BPC-157 among examples of unapproved peptide products and has included it in enforcement communications concerning gray-market peptides.

In Indonesia

The appropriate question is whether the exact finished product has a BPOM marketing authorisation or is being used within another legitimate regulatory framework.

The BPOM sources reviewed for this article did not establish an authorised BPC-157 medicinal product comparable to the traceable Wegovy or Mounjaro registrations discussed above.

That should not be rewritten as:

> “BPC-157 is illegal in Indonesia.”

That statement would make a much broader claim about possession, importation, research, manufacture and other activities than the evidence establishes.

A more accurate statement is:

> Peptides Pro did not identify a BPOM-authorised BPC-157 medicine in the official registration material reviewed for this article.

That is a product-approval statement rather than an unsupported legal conclusion.

Retatrutide is increasingly advertised by Bali peptide sellers, despite remaining investigational.

That does not make Bali's local market evidence of Indonesian approval.

In the United States, FDA currently states that retatrutide is unapproved, has not been found safe and effective for any condition and cannot be used in compounding under federal law.

Australia's TGA also lists retatrutide among unapproved peptide products and, in September 2026, reported testing a counterfeit product sold as retatrutide that actually contained undeclared semaglutide and no retatrutide.

Peptides Pro has documented the separate Bali market in Retatrutide Is Already Being Sold in Bali. But It Isn't Approved Anywhere Yet.

The important regulatory lesson is simple:

Commercial availability can arrive before marketing authorisation.

The two should never be treated as synonyms.

Peptide vendors commonly place phrases such as:

• research use only
• not for human consumption
• laboratory material

on their products.

Those words can be relevant.

But they do not provide a universal exemption from medicines law.

Regulators can consider how a product is actually presented, marketed and intended to be used.

For example, FDA warning letters have treated products marketed through peptide websites as unapproved new drugs when surrounding claims demonstrated intended human therapeutic use.

The broader lesson applies internationally:

The regulatory analysis is not determined by one disclaimer alone.

The exact product, claims, supply chain, intended use and jurisdiction matter.

A common internet assumption is:

> “If customs lets it through, it must be legal.”

That is not a reliable test.

Importation may be regulated independently from domestic medicine approval.

Australia's Personal Importation Scheme, for example, permits some unapproved therapeutic goods to be imported under specific conditions while excluding or further regulating others.

The UK requires appropriately licensed businesses to handle commercial importation of unlicensed medicinal products and requires notification to MHRA in the circumstances covered by its guidance.

Indonesia likewise has its own medicine registration, import and distribution requirements.

A parcel arriving successfully therefore does not establish that every relevant regulatory requirement has been met.

When you see a statement such as:

“This peptide is legal in Indonesia.”

ask five questions.

1. Legal for what?

Possession?

Research?

Import?

Medical prescribing?

Commercial sale?

Advertising?

These are different activities.

2. Which product?

Approval of a branded medicine containing a particular active substance does not authorise every product using that substance's name.

3. Which regulator?

For Indonesian medicinal products, BPOM is central.

An FDA statement about US law cannot substitute for an Indonesian authorisation.

4. On what date?

Peptide regulation is moving quickly.

Indonesia introduced new medicine-advertising rules in 2026.

Australia made unapproved peptides a major enforcement priority during 2026.

The US FDA has also issued multiple recent peptide-related warning letters.

A regulatory article written several years ago may now be wrong.

5. What primary source supports the claim?

Prefer:

• BPOM
• FDA
• TGA
• MHRA
• legislation
• official medicine registries

A vendor writing "legal worldwide" on its product page is not regulatory evidence.

Not necessarily.

Marketing authorisation is only one part of the law.

Possession, research, supply and importation can be governed separately.

A country-specific rule must be identified before making that claim.

No.

A prescription and regulatory marketing authorisation are separate concepts.

Some jurisdictions provide controlled routes for access to unapproved or unlicensed medicines, but those pathways do not transform the medicine into an approved product.

No.

FDA explicitly states that compounded drugs are not FDA-approved.

Not automatically.

Regulators may examine the product's intended use, claims and how it is marketed.

No.

FDA regulates the United States.

Indonesia's regulator is BPOM.

A US approval can be relevant scientific context, but Indonesian marketing authorisation must be established separately.

No.

Online markets can move faster than enforcement.

Recent TGA actions and FDA warning letters provide direct examples of products being openly marketed before regulators intervened.

There is no useful single ranking.

Different jurisdictions are stricter in different areas.

Australia has published unusually explicit peptide-specific enforcement guidance and has named compounds such as BPC-157, TB-500, retatrutide and CJC-1295 directly.

The United States has detailed drug-approval, compounding and investigational-access systems and active enforcement against sellers marketing unapproved drugs.

The UK has particularly clear restrictions around public advertising of prescription-only and unlicensed medicines, while allowing regulated "specials" in defined clinical circumstances.

Indonesia has a product-specific BPOM authorisation system, dedicated clinical-trial requirements, online-distribution controls and increasingly detailed digital medicine-advertising rules.

Calling one system simply "strictest" would hide those differences.

For someone researching peptides in Indonesia, checking whether the substance is FDA-approved is not enough.

A better order is:

1. Identify the exact compound.
2. Identify the exact finished product.
3. Search for its BPOM marketing authorisation.
4. Check the approved Indonesian indication.
5. Determine whether the activity being discussed is ordinary medical treatment, research, importation, online sale or another use.
6. Treat foreign regulatory decisions as context rather than as Indonesian law.

That approach prevents two opposite mistakes.

The first is assuming that anything unapproved is automatically criminal.

The second is assuming that anything advertised in Bali must be authorised.

Neither is reliable.

No.

Medicine approval, unapproved access, compounding, importation, advertising and online sales are governed by national and sometimes regional laws.

For medicinal products, Indonesia's National Agency of Drug and Food Control, BPOM, is the central medicines regulator.

Other Indonesian authorities and professional rules can also become relevant depending on the activity.

A blanket yes-or-no statement is not supported by the regulatory material reviewed for this article.

Peptides Pro did not identify a BPOM-authorised BPC-157 medicinal product in the official product-registration material reviewed.

That is not the same as establishing the legality of every form of possession, laboratory research, importation or other activity involving BPC-157.

Yes, specific Mounjaro KwikPen products containing tirzepatide have BPOM marketing authorisation.

BPOM records show initial approval for type 2 diabetes in February 2026 and an additional weight-management indication in July 2026.

Peptides Pro did not identify a BPOM marketing authorisation for a retatrutide medicinal product in the official Indonesian sources reviewed for this article.

The FDA also currently describes retatrutide as investigational and unapproved in the United States.

Potentially, depending on the jurisdiction and circumstances.

Examples include authorised clinical trials, FDA Expanded Access in the US, TGA Special Access or Authorised Prescriber pathways in Australia and the UK's regulated unlicensed "specials" system.

Those are controlled pathways, not general permission for unrestricted commercial sale.

Not automatically.

The product's claims, intended use, classification, supply pathway and applicable national rules all matter.

No.

FDA rules govern the United States.

Indonesian regulatory status should be checked against BPOM and relevant Indonesian law.

Peptide regulation is not a global yes-or-no list.

The same molecule can be:

• an active ingredient in an approved medicine
• an investigational drug in a clinical trial
• an unapproved product sold online
• available through a special-access programme
• restricted from advertising
• subject to import controls

depending on the product, jurisdiction and activity.

Indonesia is a particularly useful example.

BPOM has clearly authorised specific peptide-based medicines such as Wegovy and Mounjaro.

At the same time, Bali's online market includes experimental compounds that should not inherit the regulatory status of those approved medicines simply because they are also called peptides.

The US, Australia and UK demonstrate different ways regulators deal with the same problem.

Australia has become particularly explicit about unapproved gray-market peptides.

The US separates drug approval, compounding and investigational access.

The UK allows tightly controlled access to some unlicensed medicines while maintaining strong restrictions on public promotion.

The most accurate question is therefore never simply, “Is this peptide legal?”

It is:

“What exact product is this, what activity is taking place, what jurisdiction applies, and what does that regulator currently say?”

That question produces a much more reliable answer.

1. Indonesia — BPOM: Mounjaro KwikPen registration records and BPOM's July 2026 announcement confirming tirzepatide authorisation for type 2 diabetes and subsequent weight management.

1. Indonesia — BPOM: Wegovy medicinal-product registration and assessment records.

1. Indonesia — BPOM: Clinical-trial requirements and PPUK process under BPOM Regulation No. 8 of 2024.

1. Indonesia — BPOM/JDIH: Regulation No. 14 of 2024 on online distribution, as amended by Regulation No. 30 of 2025.

1. Indonesia — BPOM: Regulation No. 7 of 2026 on medicine promotion and advertising.

1. United States — FDA: Current concerns with unapproved GLP-1 drugs, including retatrutide's status and compounding restrictions.

1. United States — FDA: Current safety information for BPC-157 and TB-500-related substances considered in compounding.

1. United States — FDA: Expanded Access framework for investigational drugs.

1. Australia — TGA: Peptide-products regulatory hub and official warnings concerning unapproved peptides.

1. Australia — TGA: Special Access, Authorised Prescriber, clinical-trial and Personal Importation pathways for unapproved therapeutic goods.

1. United Kingdom — MHRA: Guidance on supplying and importing unlicensed medicinal products known as "specials".

1. United Kingdom — MHRA: Rules covering public advertising of prescription-only and unlicensed medicines.

Regulatory and Medical Disclaimer

This article is for educational and research-information purposes only. It is not legal advice, medical advice or a determination of the legal status of a specific transaction, product or individual.

Peptide regulation can depend on the exact substance, formulation, intended use, product claims, import pathway, prescribing context and jurisdiction. Regulations also change.

For individual Indonesian regulatory questions, verify the exact medicinal product through BPOM and seek appropriately qualified Indonesian regulatory or legal advice where necessary.

Editorial status: Regulatory claims verified against official sources current to 3 October 2026. Final publication should still receive normal link, formatting, image and live-page QA before release.

This article is for educational purposes only and does not replace medical advice.